


PRODUCT INFORMATION



B-HT 920 (hydrochloride)

Item No. 14177

CAS Registry No.: 36085-73-1
Formal Name: 5,6,7,8-tetrahydro-6-(2-propen-1-yl)-4H-thiazolo[4,5-d]azepin-2-amine, dihydrochloride
MF: C₁₀H₁₅N₃S • 2HCl
FW: 282.2
Purity: ≥95%
UV/Vis.: λ_{max}: 225, 263 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

B-HT 920 (hydrochloride) is supplied as a crystalline solid. Aqueous solutions of B-HT 920 (hydrochloride) can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of B-HT 920 (hydrochloride) in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

B-HT 920 is a potent agonist of dopamine 2 (D₂) receptors (K_i = 5.8 nM) that shows selectivity for D₂ over D₃ and D₄ receptors.¹⁻³ It has neuroprotective and regenerative effects in animal models of Parkinson's disease.⁴ B-HT 920 is also an agonist of α₂-adrenergic receptors and an antagonist of serotonin-3 (5-HT₃; K_i = 0.35 μM) receptors.^{5,6}

References

1. Maina, F.K., and Mathews, T.A. A functional fast scan cyclic voltammetry assay to characterize dopamine D₂ and D₃ autoreceptors in the mouse striatum. *ACS Chem Neurosci.* **1(6)**, 450-462 (2010).
2. Mewshaw, R.E., Kavanagh, J.J., Stack, G., *et al.* New generation dopaminergic agents. 1. Discovery of a novel scaffold which embraces the D₂ agonist pharmacophore. Structure-activity relationships of a series of 2-(aminomethyl)chromans. *J. Med. Chem.* **40(26)**, 4235-4256 (1997).
3. Robertson, G.S., Tham, C.S., Wilson, C., *et al.* In vivo comparisons of the effects of quinpirole and the putative presynaptic dopaminergic agonists B-HT 920 and SND 919 on striatal dopamine and acetylcholine release. *J. Pharmacol. Exp. Ther.* **264(3)**, 1344-1351 (1993).
4. Kitamura, Y. Dopaminergic neuroprotection and reconstruction of neural network tiara. *Yakugaku Zasshi* **130(10)**, 1263-1272 (2010).
5. Nishio, H., Kohno, Y., Fujii, A., *et al.* 5-HT₃ receptor blocking properties of the antiparkinsonian agent, talipexole. *Gen. Pharmacol.* **27(5)**, 778-785 (1996).
6. Rocco, D., and Taira, C.A. Adrenoceptor involvement in the cardiovascular responses to B-HT 920 in sinoaortic denervated rats. *Gen. Pharmacol.* **32(1)**, 29-34 (1999).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/21/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM